Core Insights - Merit Medical Systems, Inc. reported a revenue of $355.4 million for Q1 2025, reflecting a 9.8% increase compared to Q1 2024 [4][6] - The company achieved a constant currency revenue growth of 10.9% and an organic constant currency revenue increase of 6.0% year-over-year [4][6] - Non-GAAP earnings per share (EPS) rose by 14.8% to $0.86, while GAAP EPS increased by 2.0% to $0.49 [6][9] Financial Performance - The GAAP operating margin improved to 11.5% from 11.1% in the prior year, while the non-GAAP operating margin increased to 19.3% from 17.0% [6][8] - Free cash flow generation was reported at $19.5 million, down 20.5% compared to the previous year [6] - The company’s GAAP net income for Q1 2025 was $30.1 million, compared to $28.2 million in Q1 2024 [9] Revenue Breakdown - Revenue by segment showed significant growth in the Cardiovascular segment, with a 10.6% increase in Cardiac Intervention and a 20.5% increase in OEM [5] - The Endoscopy segment also saw substantial growth, with revenue increasing by 64.2% [7] - Total revenue for the Cardiovascular segment was $338.7 million, up 8.1% year-over-year [5] Guidance and Outlook - The company reaffirmed its total revenue guidance for 2025, projecting revenues between $1.470 billion and $1.490 billion, representing an 8% to 10% year-over-year increase [11] - Non-GAAP EPS guidance was updated to reflect stronger-than-expected Q1 results, now projected between $3.29 and $3.42 [11] - The company anticipates continued stable constant currency growth despite potential impacts from trade policies [5][11] Balance Sheet Highlights - As of March 31, 2025, Merit had cash and cash equivalents of $395.5 million, an increase from $376.7 million at the end of 2024 [10] - Total debt obligations remained stable at $747.5 million [10] - The company had an available borrowing capacity of approximately $697 million [10]

Core Viewpoint - Wall Street analysts anticipate a slight decline in Merit Medical's quarterly earnings per share, while revenues are expected to show growth compared to the previous year [1]. Earnings Estimates - Analysts expect Merit Medical (MMSI) to report earnings of $0.75 per share, reflecting a year-over-year decline of 2.6% [1]. - Revenue is projected to be $352.33 million, indicating an increase of 8.9% from the same quarter last year [1]. - The consensus EPS estimate has been revised down by 0.1% in the last 30 days, indicating a reassessment by covering analysts [1][2]. Revenue Projections - Revenue from 'Cardiovascular- Peripheral Intervention' is estimated to reach $141.95 million, a year-over-year increase of 5.4% [4]. - 'Cardiovascular- Cardiac Intervention' revenue is expected to be $98.79 million, reflecting an 8.9% increase year over year [4]. - 'Endoscopy' revenue is projected at $17.89 million, showing a significant year-over-year increase of 76.5% [5]. - 'Cardiovascular- OEM' revenue is expected to be $43.84 million, indicating an 11.6% increase from the previous year [5]. - Total 'Cardiovascular' revenue is projected to reach $334.45 million, reflecting a 6.7% year-over-year change [5]. Geographic Sales Estimates - 'Geographic Sales- United States' is estimated at $208.66 million, suggesting a year-over-year increase of 12.1% [6]. - 'Geographic Sales- International' is projected to be $143.33 million, indicating a 4.3% increase year over year [6]. Stock Performance - Over the past month, Merit Medical shares have decreased by 10.6%, compared to a 5.6% decline in the Zacks S&P 500 composite [7]. - Currently, MMSI holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [7].

Company Overview - Merit Medical Systems, Inc. (MMSI) has launched the Ventrax Delivery System, aimed at enhancing precision and control in pulmonary interventions, reflecting the company's commitment to improving procedural efficiency and outcomes in interventional medicine [1][2] Product Details - The Ventrax Delivery System expands MMSI's electrophysiology and cardiac rhythm management (CRM) portfolio, addressing the clinical demand for safer and more reliable pulmonary access technologies [2] - The system facilitates retrograde aortic access for catheter-based procedures, allowing precise placement of diagnostic, mapping, or treatment catheters into the left ventricle through the aorta, improving procedural accuracy [8][9] - Key features include a 95-cm sheath for navigating to critical target zones, a low-profile transition for smooth insertion, and an angled tip for enhanced reach, providing greater control during complex procedures [9] Market Context - The global cardiac rhythm management devices market was estimated at $17.17 billion in 2024, projected to grow at a CAGR of 6.4% from 2025 to 2030, driven by the rising prevalence of cardiovascular diseases and technological innovations [10][11] - The demand for advanced diagnostic tools like the Ventrax Delivery System is expected to rise as lung cancer screening and minimally invasive procedures gain traction [4] Financial Performance - MMSI currently has a market capitalization of $5.44 billion and has surpassed earnings estimates for the last four quarters, delivering an average surprise of 8.1% [5]

Merit Medical (MMSI) shares soared 8.3% in the last trading session to close at $95.79. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.1% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This maker of disposable medical devices is expected to post quarterly earnings of $0.75 per share in its upcomin ...

Company Overview - Merit Medical Systems, Inc. is a global leader in healthcare technology, founded in 1987, focusing on the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [7]. Product Launch - The company announced the US commercial release of its Ventrax Delivery System, which is the latest addition to its electrophysiology (EP) and cardiac rhythm management (CRM) portfolio [1][2]. Product Features - The Ventrax Delivery System is designed to facilitate the placement of devices used in ablation procedures for treating ventricular tachycardia (VT), a condition that contributes to a significant number of sudden cardiac deaths in the US, estimated between 184,000 and 450,000 annually [3]. - Key features of the Ventrax system include a 95-cm sheath for accessing target locations, an ultralow-profile transition for smooth insertion, and an angled tip to enhance the reach of an ablation catheter [6]. Market Context - VT ablation is one of the fastest-growing areas in electrophysiology, with many physicians adopting retrograde aortic access for VT procedures, indicating a rising demand for effective access tools in this field [7].

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardiaSOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of s ...

Financial Results Announcement - Merit Medical Systems, Inc. will release its financial results for the quarter ended March 31, 2025, after the stock market closes on April 24, 2025 [1] - An investor conference call is scheduled for the same day at 5:00 p.m. Eastern [1] Accessing the Conference Call - Pre-registration is required to access the conference call, with confirmation and dial-in details provided to registrants [2] - A live webcast and slide deck will be available for viewing [2] Company Overview - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for various medical procedures [3] - The company operates in fields such as cardiology, radiology, oncology, critical care, and endoscopy, serving customers globally with a sales force and clinical support team of over 800 individuals [3] - Merit employs approximately 7,300 people worldwide [3]

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transo ...

Merit Medical Systems (MMSI) released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), demonstrating strong performance in vascular access maintenance. Designed to enhance long-term outcomes for patients with end-stage renal disease, WRAPSODY CIE leverages advanced technology to improve vessel patency and reduce complications.This milestone underscores Merit Medical's dedication to innovation in interventional medicine. With promising clinical data, WRAPSODY CIE reinforces ...

Core Insights - Merit Medical Systems, Inc. announced the upcoming publication of six-month results from the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial in Kidney International and the twelve-month results will be presented at the Society of Interventional Radiology's 50th Annual Scientific Meeting [1][2] Group 1: Trial Overview - The WAVE trial is a multicenter, international investigational device exemption (IDE) trial evaluating the safety and efficacy of the WRAPSODY CIE over two years, involving 245 hemodialysis patients with venous outflow stenosis [3] - The trial compares the WRAPSODY CIE treatment (n=122) against standard percutaneous transluminal angioplasty (PTA, n=123) [3] Group 2: Efficacy and Safety Results - At six months, the WRAPSODY CIE demonstrated a target lesion primary patency of 89.8% compared to 62.8% for PTA (p<0.0001) and an access circuit primary patency of 72.6% versus 57.9% for PTA (p=0.015) [6] - At twelve months, the WRAPSODY CIE maintained a target lesion primary patency of 70.1% compared to 41.6% for PTA (p<0.0001) and an access circuit primary patency of 58.1% versus 34.4% for PTA (p=0.0003) [6][9] - No significant difference in safety outcomes was observed between the WRAPSODY CIE and PTA [6] Group 3: Regulatory Approval and Commercialization - The WRAPSODY CIE received premarket approval (PMA) from the FDA in December 2024 and began commercialization in the U.S. in January 2025 [7] - The device has also received the Conformité Européenne (CE) Mark for commercial use in the European Union and is available in Brazil [7] Group 4: Company Background - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures [10] - The company employs approximately 7,400 people worldwide and has a sales force and clinical support team of over 800 individuals [10]